Author Archives: admin


Stem Cell Clinic > Articles by: admin

Seattle Childrens faces widening array of lawsuits over fatal mold infections – Seattle Times

By Stem Cell Doctors

Beth Hutt is 5 months old and has never been home since her birth in August. She was born with a heart condition and rushed from Tacoma General Hospital to Seattle Childrens, where she has undergone three surgeries, beginning when she was 5 days old.

At some point during her stayat Seattle Childrens, Beth contracted an infection in her heart from the Aspergillus mold, a recurring problem that has sickened patients at the hospital as far back as 2001.

Beths parents, Katie and Micah Hutt, knew about the problems Seattle Childrens was having with Aspergillus but said it was a no-brainer to take her to Childrens.

We went into this situation believing that an issue had been found and it was fixed, Katie Hutt said.

On Wednesday, attorneys pursuing a class-action lawsuit against Childrens on behalf of the families of patients who have been sickened from the mold sought toadd Beth Hutt to the case.

The lawsuit, filed in December in King County Superior Court on behalf of four children or their estates, seeks class-action status for patients who were sickened by Aspergillus at Childrens between 2005 and 2017. A fifth patientwas added to the complaint before Beth Hutt.

In an emailed response, Seattle Childrens didnt answer questions about Beth Hutt.

We are working diligently to resolve these issues, including the claims that have been brought against Seattle Childrens related to past surgical site infections, the statement read. We are incredibly sorry for the impact this situation has had on our patients and families.

Beths second surgery was Nov. 7, three days before Childrens administrators closed three of the hospitals operating rooms,after the hospital announced it had found two possible cases of Aspergillus infections.Childrens closed the remaining operating rooms on Nov. 13 to sanitize them and inspect the air-handling system that serves the rooms.

The state Department of Health (DOH) said Wednesday that it had finished an investigation of the hospital, which it began in November after the hospital self-reported a case of Aspergillus to us. The agency said it did discover mold, but found the hospital to be following the states rules and found no evidence of deficient practices.

Last years problems with Aspergillus werent the first for Childrens. In October 2017, inspectors with the DOH cited the hospital for a serious violation over its failure to implement and monitor an effective infection prevention program.

In June 2018, Childrens closed two operating rooms and an equipment-storage room for three days after Aspergillus was detected and attributed to small gaps in the walls of the operating rooms.

Childrens problems with Aspergillus came to light again on May 18 last year, forcing it to close four operating rooms for more than six weeksbecause of the mold.

This time, the Aspergillus was attributed to a gap in the array of air filters in an air-handling unit serving the operating rooms, prompting the hospital to shut down, clean and install new units.Hospital officials wouldnt say Wednesday if those units were now installed.

Childrens chief executive, Dr. Jeff Sperring, has acknowledged 14 patients had been sickened by Aspergillus since 2001, six of whom died. He said the hospital had failed and blamed the hospital for not recognizing a connection between the infections and the air-handling units attached to its operating rooms.

One of the reasons Hutt was added to the lawsuit is because she is one of the most recent patients to be infected by the mold, which gives the complaint representation during a wider time frame, said attorney Karen Koehler, one of the lawyers handling the lawsuit.

Childrens, the regions premier pediatric hospital, faces a series of lawsuits related to the Aspergillus infections, including a suit filed in December by the family of an 11-year-old boy claiming he was infected during surgery in March 2019, and another that alleges a 4-year-old boy needed a second brain surgery in May related to his risk for Aspergillus exposure during surgery.

Aspergillus is a common mold that most people breathe daily without getting sick, but its risk to hospital patients has been known for decades. Patients with lung diseaseor weakened immune systems especially organ- or stem-cell transplant patients are at higher risk of developing Aspergillosis. In the most serious cases, symptoms range from a fever to coughing up blood, according to the Centers for Disease Control and Prevention.

The family of another patient, a teenager who played football, filed suit in late October. That suit alleges the hospital failed to take reasonably prudent measures to prevent Aspergillus from infecting their son, leaving him disabled.

Despite the Hutts frustration and anger with the hospitals administration and building services, they dont hold it against the nurses and doctors who have been working with their daughter.

We would not trade the level of care we have received for anything, said Beths father, Micah Hutt.

Beth Hutt is still at Seattle Childrens and had another surgery on Jan. 2.

Go here to read the rest:
Seattle Childrens faces widening array of lawsuits over fatal mold infections - Seattle Times

Landisa: My cancer can relapse but here’s why I am not afraid of it any longer – News24

By Stem Cell Doctors

I was diagnosed with cancer in January 2018 when, as I prepared for the year ahead, I underwent my annual medical examination and the doctor saw a lump in my groin. It turned out be lymphoma.

From walking into his office as a healthy person showing no symptoms and motivated to start the new years working schedule, the cancer diagnosis brought my life to a sudden standstill. It felt unreal.

At first, I could not share the news with family and friends, because I could not believe that this was really happening to me. For weeks I could not say the word "cancer"; I refused to read up about the disease on the internet as I was scared to stumble over statistics of survival rates which would show what my chances were.

So many questions came up (and mostly out of anger and disbelief, I must admit): "Why me? What could be the cause of this? Was the healthy lifestyle I was living in reality flawed? Should I consult more doctors in the hope of a different diagnosis?"

It was something I had to work out for myself in private. After a few months, I had to accept that these questions will change nothing. The reality was that I had lymphoma, that medical research could not yet determine a cause for my type, and that there is no such thing as some magic guarantee of eternal health so that even after 58 years of near-perfect health, cancer can also cross my path.

With the encouragement and support of family and friends, I became rocksteady with a positive outlook towards the future; with my mind and heart set on hope and faith of a full recovery so that, God willing, I will become fit enough again for regular exercise and to return to work. That this diagnosis would be not the end of the road, but only a bend in the road. That the unknown treatment and medical procedures laying ahead will not scare me but rather be an "adventure" to take head-on and endure. Little did I know then that it would involve a marathon treatment programme spanning 18 months and comprising 13 sessions of chemotherapy, 20 sessions of radiation therapy and a stem cell transplant.

Hardly could we as a family have foreseen that our lifestyle would change so dramatically: the doctors put me on a strict neutropenic diet as well as effectively confine me to my home (my weakened immune system needed protection from the risk posed by potential infection transmitted via food or people).

Add on top of that a new routine involving things such as endless blood tests, doctor's appointments, days in hospital and in the chemo-room, blood transfusions, hands full of tablets, various biopsies and scans, very painful veins and arteries, weakness and extremely low energy levels, and even the impact of a transplant procedure.

For me these tough times quickly changed into a mere memory on June 20, 2019 when the doctors declared me cancer-free. The gratefulness and relief when you hear the words "the tests show that all signs of cancer disappeared" is hard, if not impossible, to express in words.

It immediately puts the endurance into perspective.

Looking back at the past two years: what a learning curve and what an experience for me!

It made me realise the fragility of our health and the suddenness in which it can be lost; that cancer indiscriminately affects young and old alike; and that there is hope, because cancer can be cured!

Cancer fundamentally changed the way I look at life. It taught me that life is a gift handed to us one day at a time, wrapped in 24-hour packages.

It is up to us to take that gift each morning, open it up and make the best of what it holds for us on that day.

Yesterday's gift is gone forever, and tomorrow might bring something worse than today, or maybe today's gift is the last one in this life. Cancer taught me that it is not about tomorrow, it's all about today - I only have today.

And an inner peace fills me now with the realisation that I had the privilege to receive the prized and valuable gift of life.

"And once the storm is over, you wont remember how you made it through, how you managed to survive. You wont even be sure whether the storm is really over. But one thing is certain. When you come out of the storm, you wont be the same person who walked in. Thats what this storms all about." - Haruki Murakam

Do you have a story to share? Send it tolandisa@news24.comand include your contact details and a photo. VisitLandisafor more stories.

Original post:
Landisa: My cancer can relapse but here's why I am not afraid of it any longer - News24

‘You wouldn’t give it to your worst enemy’: what it’s like to live with Lyme disease – Telegraph.co.uk

By Stem Cell Doctors

When Sarah Hook was rushed to hospital in 2015, she was struggling to breathe,her heart was racing and she was experiencing an intense rush of adrenaline.I felt like I had drunk 100 coffees, she remembers.

Initially, doctors identified her symptoms as a panic attack but Hook,had never had one before. A month later, she realised theterrifying episode could in fact have been linked to a tick bite that had occurred 10 years previously.I didn't do anything about the tick bite," she says. "I left it, (but) looking back I can see that my health has been deteriorating since then. Id left it so long my body crashed.

Six months after her hospitalisation, a blood test at a private clinic confirmed that Hook had Lyme disease,a tick-borne infectious disease which can cause extreme fatigue, nerve damage, and neurological issues. Ever since, she has been unable to work and has had to move back in with her parents in Berkshire.

Its such a systemic illness, the symptoms morph and change," she says. "You can just feel like youve got rid of one and it can just pop up somewhere else. I think that's why it feels so exhausting.

This week, US singer Justin Bieber announced on Instagram that he is battling the disease.While a lot of people kept saying Justin Bieber looks like s***, on meth etc. they failed to realise I've been recently diagnosed with Lyme disease, the 25-year-old wrote, referencing speculation about his health afterpictures showed him looking exhausted, with blotchy skin.

More:
'You wouldn't give it to your worst enemy': what it's like to live with Lyme disease - Telegraph.co.uk

The ‘supercells’ that cured an infant’s grave genetic illness – Japan Today

By Stem Cell Doctors

When a person's immune system is impaired by a genetic disease, a bone-marrow transplant can be a powerful therapeutic tool, but with a major downside: during the first few months the recipient's defenses against viruses are severely weakened. The slightest infection can lead to a hospital trip.

A still-experimental type of treatment known as T-cell therapy aims to assist during this vulnerable period -- the months during which the body is rebuilding its natural defenses. After two decades of clinical trials, the technology has been refined, and is being used to treat more and more patients, many of them children.

A boy named Johan is one of them.

Today he is a mischievous, smiling toddler with a thick shock of light-brown hair, who never tires, playfully tormenting the family's puppy, Henry. There is no sign of the three-year-long medical and emotional roller-coaster ride he and his family, who live in an affluent Washington suburb, have been on.

The first traumatic surprise came with the results of a pregnancy test: Johan was not planned.

"That was a huge shock. I cried," said his mother, 39-year-old Maren Chamorro.

She had known since childhood that she carried a gene that can be fatal in a child's first 10 years, chronic granulomatous disease (CGD). Her brother died of it at the age of seven. The inexorable laws of genetics meant that Maren had a one in four chance of transmitting it to her child.

For their first children, she and her husband Ricardo had chosen in-vitro fertilization, allowing the embryos to be genetically tested before implantation.

Their twins Thomas and Joanna were born -- both disease-free -- seven and a half years ago. But in Johan's case, a post-birth genetic test quickly confirmed the worst: he had CGD.

After conferring with experts at Children's National Hospital in Washington, the couple took one of the most important decisions of their lives: Johan would receive a bone-marrow transplant, a risky procedure but one that would give him a chance of a cure.

"Obviously, the fact that Maren had lost a sibling at a young age from the disease played a big role," Ricardo confided.

Bone marrow, the spongy tissue inside bones, serves as the body's "factory" for the production of blood cells -- both red and white.

Johan's white blood cells were incapable of fighting off bacteria and fungal infections. A simple bacterial infection, of negligible concern in a healthy child, could spread out of control in his young body.

Luckily, Johan's brother Thomas, six years old at the time, was a perfect match. In April 2018, doctors first "cleansed" Johan's marrow using chemotherapy. They then took a small amount of marrow from Thomas's hip bones using a long, thin needle.

From that sample they extracted "supercells," as Thomas calls them -- stem cells, which they reinjected into Johan's veins. Those cells would eventually settle in his bone marrow -- and begin producing normal white blood cells.

The second step was preventive cell therapy, under an experimental program led by immunologist Michael Keller at Children's National Hospital.

The part of the immune system that protects against bacteria can be rebuilt in only a matter of weeks; but for viruses, the natural process takes at least three months.

From Thomas's blood, doctors extracted specialized white blood cells -- T-cells -- that had already encountered six viruses.

Keller grew them for 10 days in an incubator, creating an army of hundreds of millions of those specialized T-cells. The result: a fluffy white substance contained in a small glass vial.

Those T-cells were then injected into Johan's veins, immediately conferring protection against the six viruses.

"He has his brother's immune system," said Keller, an assistant professor at Children's National.

Johan's mother confirmed as much: today, when Thomas and Johan catch a cold, they have the same symptoms, and for nearly the same amount of time.

"I think it's pretty cool to have immunity from your big brother," Maren Chamorro said.

This therapeutic approach -- boosting the body's immune system using cells from a donor or one's own genetically modified cells -- is known as immunotherapy.

Its main use so far has been against cancer, but Keller hopes it will soon become available against viruses for patients, like Johan, who suffer from depressed immune systems.

The chief obstacles to that happening are the complexity of the process and the costs, which can run to many thousands of dollars. These factors currently restrict the procedure to some 30 medical centers in the United States.

For Johan, a year and a half after his bone marrow transplant, everything points to a complete success.

"It's neat to see him processing things, and especially play outside in the mud," his mother said. "You know, what a gift!"

Her only concern now is the same as any mother would have -- that when her son does fall ill, others in the family might catch the same bug.

Read this article:
The 'supercells' that cured an infant's grave genetic illness - Japan Today

Everything You Need To Know About A Non-Surgical Eyelid Lift – BEAUTYcrew

By Platelet Rich Plasma Injections

Thanks to the effects of sun damage, pollution, mindless rubbing (guilty), heavy-handed makeup removal (also guilty) and ageing, the skin around your eyes is the first area to show signs of decline. Were talking wrinkles, sagging and all the good stuff that makes you look even more tired than you actually are. Cool!

While the promise of youthful, taut, post-eyelid lift skin might sound like the best option going, if youre anything like us, you'll most likely be put off by the cost, risks and downtime involved. Because guys, surgery is a big deal, and theres no going back once the procedure has been performed.

But there are other options out there. Unlike eyelid lift surgery (which is also known as a blepharoplasty), plasma eyelid lift is the latest non-surgical procedure that helps tighten the eyelid skin, minimising the effects of eye ageing. The best part? It involves no incisions and requires minimal downtime.

A plasma eyelid lift is a procedure used to tighten, lift and rejuvenate the skin on the upper eyelid, all without surgery. And just FYI while it sounds like were talking about plasma found in the blood, were actually talking about plasma as a high-energy current. The fourth state of matter, plasma is an ionised gas able to conduct a large and sustained electrical current. The sun, fire and lightning bolts are examples of plasma, explains Natalie Abouchar, registered nurse and founder of Prive Clinic.

Without touching the skin, a hand-held device (which looks like a small pen) is moved over the surface of the eyelid to tighten the skin and encourage collagen production. The pen works by ionising gases in the air to create a small electrical arc, similar to a lightning bolt, that can be used to rejuvenate problem areas without damaging the surrounding areas, says Abouchar. The pen projects an ionised, low frequency plasma arc onto the skin surface, vaporising the skin at the point of contact and resulting in an instant contraction and tightening of skin fibres.

Feeling a little bit lost? To break it down, the device basically heats the dermis in the target area (your eyelids), which then sheds post treatment, tightening the skin and allowing fresher skin to form.

The treatment is fairly versatile and can be used on all different areas of the face (such as frown lines, nasolabial folds and crows feet), and can treat a wide range of skin conditions, including laxity and loss of texture. According to Abouchar, when used on the eye region the plasma eyelid lift can effectively reduce the amount of lax skin on hooded upper eyelids. Overall, it gives the eyes a more youthful, open and awake appearance.

According to Abouchar the procedure is suitable for people who are in the early stages of eye drooping with skin types one to three (people with pale white skin, fair skin and darker white skin). If the skin above the eyes is very heavy, a surgical eyelid lift may be a more appropriate treatment. During your consultation, your doctor or nurse will analyse your skin and let you know if you are a suitable candidate for this treatment.

Topical anaesthetic cream is applied prior to the ACCOR Plasma Pen Non-Surgical Eyelid Lift. This is left on for approximately 30 minutes. The treatment is then performed by placing dots in a particular pattern on the eyelid and lateral temple region. After it is completed, a powder and setting spray is applied to cover the dots and help heal the tissue.

Most people can expect around five days of downtime in which makeup cannot be worn. Redness and swelling will occur immediately post-treatment, with swelling peaking over the two days following treatment, says Abouchar. Its important not to ice the area as the swelling is an important part of the process. There will also be noticeable dot marks in the treatment area. These tiny, pinprick dots are portions of ablated tissue, formed into scabs. These last for around four to seven days and youll need to avoid picking them or getting them wet to prevent scarring. Once the scabs have fallen off, you can resume normal activities and wear makeup to cover any redness that may remain.

Abouchar says two treatments are generally required, however, whether or not more treatments are needed will depend on the degree of laxity. The full effect of the initial treatment is visible after 12 weeks. At this point, a second tightening and lifting treatment may be performed, if required.

If the plasma eyelid lift treatment doesnt sound like your jam, dont worry theres still a bunch of other non-surgical alternatives to going under the knife. Non-surgical eye rejuvenation can be achieved with a mix of anti-wrinkle injections and dermal fillers. Injecting a neurotoxin superficially into the orbicularis oculi muscle (just under the eyebrow and lateral to the eye) and into the glabella (the frown lines) will relax the muscles responsible for a drooping eye area, explains Abouchar. This results in a lifting of the eyebrows and a fresher, more youthful appearance. Dermal fillers can also be injected into the temple and deep under the muscle on the brow to lift the eyebrows and create a more open-eyed look.

Radio frequency can also be used to lift and tighten loose skin around the eyes. Here, a combination of skin needling and radio frequency energy triggers the bodys natural healing response, thus stimulating collagen and elastin production. The radio frequency causes a thermal reaction in the tissue, resulting in tighter skin, reduced fine lines and a brighter, more radiant eye contour, says Abouchar.

Platelet rich plasma (PRP) is another non-surgical option that can be used to tighten sagging skin on the face (you can read more about whats involved in a PRP treatment here). A 100 per cent natural option, vampire injections (using your own blood) can also be used to thicken and strengthen sagging, crepey skin in the eye contour and boost collagen for a reduction in fine lines and wrinkles.

For more non-surgical treatment options, check out everything you need to know about thread lifts.

Main image credit: Getty

Original post:
Everything You Need To Know About A Non-Surgical Eyelid Lift - BEAUTYcrew

CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -…

By Induced Pluripotent Stem Cells

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Click to copy

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The New York Stem Cell Foundation (NYSCF) Research Institute today announced a partnership with Cytovia Therapeutics Inc. (Cytovia) to develop new disease treatments that leverage human stem cell research and novel gene editing techniques. NYSCF will be a key partner to Cytovia in using stem cells to advance novel therapeutic targets for cancer.

Cytovia leverages NK cells to make these novel therapeutics more specific to cancer cells. NK or natural killer cells are immune cells that scan the body and attack infected or abnormal cells, often serving as a first line of defense against cancer. CAR (chimeric antigen receptor) NK cells are genetically engineered to better locate and attack tumors. CAR NK-based treatments are currently showing promise in clinical trials and could serve as a potent and cost-efficient alternative to current immunotherapies. Establishing high-quality, stem-cell-derived NKs and CAR NKs will help improve these treatments and accelerate their path to the clinic.

The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array, the premier automated robotic platform for reprogramming adult cells into induced pluripotent stem cells (iPSCs). These iPSCs carry the genetic blueprint of the person from whom they are derived and can be turned into any cell type in the body, allowing scientists to study disease mechanisms in affected cells or modify them for use in therapeutics.

Our mission is to bring lifesaving treatments to patients around the world and we are excited to further this goal in partnership with Cytovia, says NYSCF CEO and founder Susan L. Solomon. It is critical that we collaborate with partners using our technology and expertise to bring innovative treatments to the market.

We are delighted to collaborate with the NYSCF Research Institute to develop iPSC-derived NK and CAR NK therapeutics, says Dr. Daniel Teper, CEO of Cytovia. By integrating NYSCFs world-class stem cell know-how and the precision gene-editing research conducted at the University of California San Francisco, Cytovia aims to become a leader in NK cell therapeutics for the treatment of cancer.

About The New York Stem Cell Foundation Research Institute The New York Stem Cell Foundation (NYSCF) Research Institute is an independent non-profit organization accelerating cures and better treatments for patients through stem cell research. The NYSCF global community includes over 190 researchers at leading institutions worldwide, including the NYSCF Druckenmiller Fellows, the NYSCF Robertson Investigators, the NYSCF Robertson Stem Cell Prize Recipients, and NYSCF Research Institute scientists and engineers. The NYSCF Research Institute is an acknowledged world leader in stem cell research and in the development of pioneering stem cell technologies, including the NYSCF Global Stem Cell Array, which is used to create cell lines for laboratories around the globe. In 2019, NYSCF launched its Womens Reproductive Cancers Initiative, which aims to shift paradigms in the way these cancers are studied and treated, in collaboration with leading cancer experts across the globe. NYSCF focuses on translational research in an accelerator model designed to overcome barriers that slow discovery and replace silos with collaboration. For more information, visit http://www.nyscf.org.

About Cytovia Therapeutics Inc. Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies. Learn more at cytoviatx.com

Contact information:CYTOVIA Therapeutics:Anna Baran-DjokovicVP, Corporate Affairs anna@cytoviatx.com

Cytovia Media Contact: Charlotte Tomic charlotte@tomiccommmunications.com Cell: 9178825243

NYSCF Research InstituteDavid McKeonChief of Staff dmckeon@nyscf.org

Continue reading here:
CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -...

Stem Cells Market Segmentation and Analysis Report, 2025 – Food & Beverage Herald

By Induced Pluripotent Stem Cells

In theglobalstem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request PDF Sample of Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Enquiry for Discount on Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

This post was originally published on Food and Beverage Herald

Read more:
Stem Cells Market Segmentation and Analysis Report, 2025 - Food & Beverage Herald

Stem Cell Therapy Market Robust Growth Counted to 2025 – Instanews247

By Induced Pluripotent Stem Cells

Stem Cell Therapy Market research now available at Industry Stats Report encompasses an exhaustive Study of this business space with regards to pivotal industry drivers, market share analysis, and the latest trends characterizing the Stem Cell Therapy industry landscape. This report also covers details of market size, growth spectrum, and the competitive scenario of Stem Cell Therapy market in the forecast timeline.

Request for Sample of this [emailprotected] https://industrystatsreport.com/Request/Sample?ResearchPostId=595&RequestType=Sample

The well-established Key players in the market are:

Gilead Novartis Organogenesis Vericel Others

This report for Stem Cell Therapy Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

Reports include the following segmentation: By Product Type Adult Stem Cells Human Embryonic Stem Cells (hESC) Induced Pluripotent Stem Cells Very Small Embryonic Like Stem CellsBy Applications Type Regenerative Medicine Drug Discovery and DevelopmentBy Technology Cell Acquisition Cell Production Cryopreservation Expansion and Sub-CultureBy Cell Therapy Autologous AllogeneicBy Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

Request Customization of this Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=595&RequestType=Customization

Some Main Reasons for Purchasing This Report:

New ways and approaches appropriate within the advancement structure of themarket.

Readers of this report will receive in-depth knowledge about the market.

Updated statistics offered on the global market report.

This report provides an insight into the market that will help you boost your companys business and sales activities.

It will help you to find prospective partners and suppliers.

It will assist and strengthen your companys decision-making processes.

More Details on this Report: https://industrystatsreport.com/Semiconductor-and-Electronics/Stem-Cell-Therapy-Market-Share/Summary

Worldwide Market Report Provides Comprehensive Analysis of:

Functional market industry outline

Up and downstream industry examination

Channels and propositions believability

Market challenge by key players

Enhancement suggestions examination

The report outlines the regulatory framework surrounding and governing numerous aspects of the market. At the end, Stem Cell Therapy industry development rival view, the industry scenario, samples, research conclusions are described. The important examination incorporated from 2014 to 2019 and till 2024 makes the report helpful assets for industry officials, promoting, sales, directors, experts, trade consultants, and others looking for key industry information with clearly given tables and charts.

More Report: https://www.marketwatch.com/press-release/smart-eyewear-technology-market-size-share-application-analysis-regional-outlook-growth-upcoming-trends-key-players-and-competitive-strategiesforecast-to-2025-2019-08-13

Read More Report:

https://www.marketwatch.com/press-release/investment-casting-market-size-segmented-by-product-type-top-manufacturers-by-end-user-industry-geography-trends-and-forecast-2025-2020-01-09

Read More Report:

https://www.marketwatch.com/press-release/surgical-anti-adhesion-products-market-2019-latest-innovations-analysis-by-key-manufacturers-commercial-sector-overview-component-industry-revenue-and-forecast-to-2025-2020-01-09

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact US:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.

Kemp House, 152 160 City Road, London EC1V 2NX

+44-2038074155

[emailprotected]

Follow this link:
Stem Cell Therapy Market Robust Growth Counted to 2025 - Instanews247

The Top Biotech Trends We’ll Be Watching in 2020 – Singularity Hub

By Induced Pluripotent Stem Cells

Last year left us with this piece of bombshell news: He Jiankui, the mastermind behind the CRISPR babies scandal, has been sentenced to three years in prison for violating Chinese laws on scientific research and medical management. Two of his colleagues also face prison for genetically engineering human embryos that eventually became the worlds first CRISPRd babies.

The story isnt over: at least one other scientist is eagerly following Hes footsteps in creating gene-edited humans, although he stresses that he wont implant any engineered embryos until receiving regulatory approval.

Biotech stories are rarely this dramatic. But as gene editing tools and assisted reproductive technologies increase in safety and precision, were bound to see ever more mind-bending headlines. Add in a dose of deep learning for drug discovery and synthetic biology, and its fair to say were getting closer to reshaping biology from the ground upboth ourselves and other living creatures around us.

Here are two stories in biotech were keeping our eyes on. Although successes likely wont come to fruition this year (sorry), these futuristic projects may be closer to reality than you think.

The idea of human-animal chimeras immediately triggers ethical aversion, but the dream of engineering replacement human organs in other animals is gaining momentum.

There are two main ways to do this. The slightly less ethically-fraught idea is to grow a fleet of pigs with heavily CRISPRd organs to make them more human-like. It sounds crazy, but scientists have already successfully transplanted pig hearts into baboonsa stand-in for people with heart failurewith some recipients living up to 180 days before they were euthanized. Despite having foreign hearts, the baboons were healthy and acted like their normal buoyant selves post-op.

But for cross-species transplantation, or xenotransplants to work in humans, we need to deal with PERVsa group of nasty pig genes scattered across the porcine genome, remnants of ancient viral infections that can tag along and potentially infect unsuspecting human recipients.

Theres plenty of progress here too: back in 2017 scientists at eGenesis, a startup spun off from Dr. George Churchs lab, used CRISPR to make PERV-free pig cells that eventually became PERV-free piglets after cloning. Then last month, eGenesis reported the birth of Pig3.0, the worlds most CRISPRd animal to further increase organ compatibility. These PERV-free genetic wonders had three pig genes that stimulate immunorejection removed, and nine brand new human genes to make themin theorymore compatible with human physiology. When raised to adulthood, pig3.0 could reproduce and pass on their genetic edits.

Although only a first clinical propotype that needs further validation and refinement, eGenesis is hopeful. According to one (perhaps overzealous) estimate, the first pig-to-human xenotranplant clinical trial could come in just two years.

The more ethically-challenged idea is to grow human organs directly inside other animalsin other words, engineer human-animal hybrid embryos and bring them to term. This approach marries two ethically uncomfortable technologies, germline editing and hybrids, into one solution that has many wondering if these engineered animals may somehow receive a dose of humanness by accident during development. What if, for example, human donor cells end up migrating to the hybrid animals brain?

Nevertheless, this year scientists at the University of Tokyo are planning to grow human tissue in rodent and pig embryos and transplant those hybrids into surrogates for further development. For now, bringing the embryos to term is completely out of the question. But the line between humans and other animals will only be further blurred in 2020, and scientists have begun debating a new label, substantially human, for living organisms that are mainly human in characteristicsbut not completely so.

With over 800 gene therapy trials in the running and several in mature stages, well likely see a leap in new gene medicine approvals and growth in CAR-T spheres. For now, although transformative, the three approved gene therapies have had lackluster market results, spurring some to ponder whether companies may cut down on investment.

The research community, however, is going strong, with a curious bifurcating trend emerging. Let me explain.

Genetic medicine, a grab-bag term for treatments that directly change genes or their expression, is usually an off-the-shelf solution. Cell therapies, such as the blood cancer breakthrough CAR-T, are extremely personalized in that a patients own immune cells are genetically enhanced. But the true power of genetic medicine lies in its potential for hyper-personalization, especially when it comes to rare genetic disorders. In contrast, CAR-Ts broader success may eventually rely on its ability to become one-size-fits-all.

One example of hyper-tailored gene medicine success is the harrowing story of Mila, a six-year-old with Batten disease, a neurodegenerative genetic disorder that is always fatal and was previously untreatable. Thanks to remarkable efforts from multiple teams, however, in just over a year scientists developed a new experimental therapy tailored to her unique genetic mutation. Since receiving the drug, Milas condition improved significantly.

Milas case is a proof-of-concept of the power of N=1 genetic medicine. Its unclear whether other children also carry her particular mutationBatten has more than a dozen different variants, each stemming from different genetic miscodingor if anyone else would ever benefit from the treatment.

For now, monumental costs and other necessary resources make it impossible to pull off similar feats for a broader population. This is a shame, because inherited diseases rarely have a single genetic cause. But costs for genome mapping and DNA synthesis are rapidly declining. Were starting to better understand how mutations lead to varied disorders. And with multiple gene medicines, such as antisense oligonucleotides (ASOs) finally making a comeback after 40 years, its not hard to envision a new era of hyper-personalized genetic treatments, especially for rare diseases.

In contrast, the path forward for CAR-T is to strip its personalization. Both FDA-approved CAR-T therapies require doctors to collect a patients own immune T cells, preserved and shipped to a manufacturer, genetically engineered to boost their cancer-hunting abilities, and infused back into patients. Each cycle is a race against the cancer clock, requiring about three to four weeks to manufacture. Shipping and labor costs further drive up the treatments price tag to hundreds of thousands of dollars per treatment.

These considerable problems have pushed scientists to actively research off-the-shelf CAR-T therapies, which can be made from healthy donor cells in giant batches and cryopreserved. The main stumbling block is immunorejection: engineered cells from donors can cause life-threatening immune problems, or be completely eliminated by the cancer patients immune system and lose efficacy.

The good news? Promising results are coming soon. One idea is to use T cells from umbilical cord blood, which are less likely to generate an immune response. Another is to engineer T cells from induced pluripotent stem cells (iPSC)mature cells returned back to a young, stem-like state. A patients skin cells, for example, could be made into iPSCs that constantly renew themselves, and only pushed to develop into cancer-fighting T cells when needed.

Yet another idea is to use gene editing to delete proteins on T cells that can trigger an immune responsethe first clinical trials with this approach are already underway. With at least nine different off-the-shelf CAR-T in early human trials, well likely see movement in industrialized CAR-T this year.

Theres lots of other stories in biotech we here at Singularity Hub are watching. For example, the use of AI in drug discovery, after years of hype, may finally meet its reckoning. That is, can the technology actually speed up the arduous process of finding new drug targets or the design of new drugs?

Another potentially game-changing story is that of Biogens Alzheimers drug candidate, which reported contradicting results last year but was still submitted to the FDA. If approved, itll be the first drug to slow cognitive decline in a decade. And of course, theres always the potential for another mind-breaking technological leap (or stumble?) thats hard to predict.

In other words: we cant wait to bring you new stories from biotechs cutting edge in 2020.

Image Credit: Image by Konstantin Kolosov from Pixabay

Go here to see the original:
The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub

Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami – Yahoo Finance

By Stem Cell Medical Center

2020 Honorees include Cystic Fibrosis Foundation, Emily Whitehead Foundation, Gift of Life Marrow Registry and Ret. Major General Bernard Burn Loeffke (US Military)

Miami, FL, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The formal ceremony of the 2020 Stem Cell and Regenerative Medicine Action Awards will take place at a gala reception and dinner on January 23, during the 15th annual World Stem Cell Summit (WSCS) at the Hyatt Regency in Miami. Since 2005, the nonprofit Regenerative Medicine Foundation (RMF) (formerly Genetics Policy Institute) has recognized the stem cell and regenerative medicine community's leading innovators, leaders, and champions through its annual awards reception.

Bernard Siegel, Executive Director of Regenerative Medicine Foundation and founder of the World Stem Cell Summit, said, The 2020 Action Awards will recognize three important organizations that are positively impacting the emerging field of regenerative medicine. We will also honor a retired Major General, who has capped off his military and diplomatic career by promoting the cause of world peace through medicine. All of these distinguished honorees will be recognized for their devotion to improving health and developing cures through advocacy, innovation, leadership and inspiration. In addition, the wounded warrior veterans community of South Florida will also receive special recognition at the event.

Meet the 2020 Stem Cell & Regenerative Medicine Action Award Honorees:

Innovation Award: With the motto, We will not rest until we find a cure, the Cystic Fibrosis Foundation is geared towards the successful development and delivery of treatments, therapies and a cure for every person with cystic fibrosis. CF Foundation has added decades to the lives of people with the disease as a direct result of advances in treatment and care made possible through its innovative business model- venture philanthropy. The Foundation recently unveiled its Path to a Cure research agenda aimed at addressing the root genetic cause of the disease and is currently funding industry programs aimed at gene delivery with the goal of progressing into clinical studies in 2021.

Inspiration Award: Emily Whitehead Foundation is a nonprofit organization committed to raising funds to invest in the most promising pediatric cancer research. Tom and Kari Whitehead founded EWF in honor of their daughter Emily, the first child in the world to receive CAR T-cell therapy, training her own cells to fight cancer. Her inspiring story focused public attention on thepotential for cancer immunotherapy to transform cancer treatment,as well as the need to support lifesaving cancer immunotherapy research. The foundation provides support to pediatric cancer patients and promotes awareness of the disease through education and sharing other inspiring stories.

Advocacy Award: Gift of Life Marrow Registry was established in 1991 by Jay Feinberg and his family after Jay received a life-saving bone marrow transplant. Gift of Life is dedicated to saving lives and facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, sickle cell and other diseases. In 2019, Gift of Life opened the worlds first apheresis center fully integrated within a registry, the Dr. Miriam and Sheldon G. Adelson Gift of Life-Be The Match Stem Cell Collection Center. With the collection center and rapidly expanding donor database, Gift of Life will launch a biobank to advance cellular therapies using allogeneically sourced cells in 2020.

Leadership Award: Ret. Major General Bernard Burn Loeffke, PhD (US Military) is a highly decorated Special Forces officer, diplomat and medical officer.He survived two helicopter crashes and was wounded in combat. After the Vietnam War, he served as the Army Attach at theU.S. Embassy in Moscow, first Defense Attach at the U.S Embassy in Beijing, a staff officer in theWhite House, and Director of the Commission onWhite House Fellows. His last command was Commanding General of Army South. After 35 years in the military, he became a medical officer traveling the world on relief missions to third and fourth world countries. Presently, at age 85, he champions the hydrocephalus and wounded warrior communities. He continues to serve as an inspiration and supporter of building peaceful international relations through medical partnerships and played a pivotal role as a keynote speaker at the inaugural 2019 World Stem Cell Summit CHINA.He is called the Peace General in Latin America. In China, he is simply known as The General, our Friend.

Story continues

To learn more about past honorees and details for sponsoring or attending the upcoming 2020 Stem Cell and Regenerative Medicine Action Awards dinner, please visit, https://www.worldstemcellsummit.com/stem-cell-action-awards/

About the World Stem Cell Summit (WSCS)

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: http://www.worldstemcellsummit.com.

About the Regenerative Medicine Foundation (RMF)

The nonprofit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF unites the worlds leading researchers, medical centers, universities, labs, businesses, funders, policymakers, experts in law, regulation and ethics, medical philanthropies, and patient organizations. We maintain a trusted network of leaders and pursue our mission by producing our flagship World Stem Cell Summit series of conferences and public days, honoring leaders through the Stem Cell and Regenerative Medicine Action Awards, supporting our official journal partner STEM CELLS Translational Medicine (SCTM), promoting solution-focused policy initiatives both nationally and internationally and creating STEM/STEAM educational projects. For more information about RMF, please visit: http://www.regmedfoundation.org.

Attachments

Joseph DawsonRegenerative Medicine Foundation561-906-4755joseph@regmedfoundation.org

Here is the original post:
Stem Cell and Regenerative Medicine Action Awards to be Presented at World Stem Cell Summit on January 23 at the Hyatt Regency Miami - Yahoo Finance

→←